Searchable abstracts of presentations at key conferences in endocrinology

ea0089b15 | Basic Science | NANETS2022

Targeting the TCA Cycle with Histone Deacetylase and Nicotinamide Phosphoribosyltransferase Inhibitors Uncovers a Critical Role for YAP1 in Neuroendocrine Cells

Scotto PhD Luigi , Safari PhD Maryam , Hou Ping , Fojo, MD PhD Tito , Bates MD Susan

Background: More than 12,000 people in the United States are diagnosed with a NET each year and approximately 175,000 people are living with this diagnosis. Little progress has been made in the therapy of NETs over the last two decades, and identification of new vulnerabilities remains a priority.Methods: We used two libraries of compounds selected for potential repurposing and identified agents with the highest cytotoxic activity in neuroendocrine model...

ea0035p71 | Bone and Osteoporosis | ECE2014

Bone mineral density in Iranian patients: effects of age, sex, and BMI

Aghaei Mehrdad , Bazrafshan Hamidreza , Qorbani Mostafa , Shojaa Mahdieh , Dashti Hossien Shadpour , Sarmadi Payam , Safari Roya

Introduction: Osteoporosis is a multifactorial skeletal disease that is characterized by reduced bone mineral density (BMD). BMD values depend on several factors such as age, sex and age at menopause. The purpose of this study was to determine the prevalence and changes in BMD in Iranian patients.Methods: Three hundred patients were selected through random sampling technique in 2009. BMD was assessed by Norland machine at the lumbar and femoral neck. Wei...

ea0011p433 | Endocrine disruptors | ECE2006

A randomized, open-label, multicenter study to evaluate octreotide LAR with surgical therapy as primary therapy patients with acromegaly

Colao A , Bouterfa H , Cappabianca P , Caron P , De Menis E , Farrall A , Gadelha M , Reed A , Reincke M , Safari M , T’Sjoen G , Cuneo R

This is the first prospective study to compare the efficacy and safety of medical therapy and surgery as primary therapy in acromegaly.A total of 104 patients with untreated acromegaly were enrolled. Eighty-one patients randomized to receive either octreotide LAR 20 mg (n=40) or surgery (n=41) completed the 48 weeks treatment period, and constituted the population used for this analysis, regardless of response to treatment.<p class="abs...